SEC Filing Summary: BioSig Technologies, Inc. (BSGM)
Business Context and Reporting Period
This Form 8-K Current Report was filed on November 2, 2023, by BioSig Technologies, Inc. (not Streamex Corp.). The registrant is a Delaware corporation headquartered in Westport, Connecticut, with common stock trading on the NASDAQ Capital Market under the symbol BSGM. The report discloses a material business development under Item 7.01 (Regulation FD Disclosure).
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on a strategic business announcement rather than financial performance results.
Material Changes and Business Developments
- Strategic Partnership Upgrade: Mayo Clinic-Phoenix, an existing user of the Company's PURE EP™ Platform, has upgraded to the Platform's subscription model.
- Operational Impact: This upgrade grants the client immediate access to the Company's latest technological advancements in cardiac arrhythmia identification.
Guidance, Outlook, and Risks
The Company explicitly states it undertakes no obligation to update, supplement, or amend the materials attached to this report. The filing includes standard disclaimers noting that the information is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not intended to constitute a determination of materiality under Regulation FD. No specific financial guidance or risk factors were detailed in this specific document.
Investor Verification Checklist
- Verify the exact terms and financial value of the subscription upgrade with Mayo Clinic-Phoenix, as these details are not disclosed in the 8-K text.
- Confirm the total number of active subscription users for the PURE EP™ Platform to assess the significance of this single upgrade.
- Review the attached Exhibit 99.1 (Press Release) for additional qualitative details regarding the technology advancements.
- Check subsequent filings (10-Q or 10-K) for the financial impact of this subscription model on recurring revenue.